drugset / Trial / NCT03214380

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

NCT03214380

Phase 3 Completed 933 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).

Timeline

Start
2017-07-14
Primary completion
2018-08-14
Completion
2019-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous
Background Metformin Small molecule Oral
Background insulin degludec Protein / enzyme biologic Subcutaneous
Background insulin glargine Protein / enzyme biologic Subcutaneous